FDA Eases Cell Therapy Rules as Market Forecast Hits $14B by 2035
FDA loosened cell and gene therapy manufacturing rules, enabling concurrent lot releases and easing process validation to accelerate commercial launches. The global cell therapy manufacturing market is expected to grow from $7 billion in 2026 to $14 billion by 2035, potentially boosting capacity-constrained developers like Moleculin Biotech.
1. Regulatory Flexibility Introduced
The FDA has implemented new measures to streamline cell and gene therapy manufacturing, allowing concurrent lot releases and relaxing certain process validation requirements. These changes aim to reduce time from lab development to commercial launch and address historical supply bottlenecks.
2. Market Growth Projections
Analysts project the global cell therapy manufacturing market will expand from $7 billion in 2026 to $14 billion by 2035, driven by over 1,000 clinical candidates and rising demand for scalable GMP infrastructure. Companies with robust manufacturing foundations are poised to capture significant market share.
3. Impact on Moleculin Biotech
Moleculin Biotech, facing tight biologics capacity constraints, stands to benefit from eased FDA rules as it scales its cancer and antiviral therapies. Improved manufacturing flexibility could accelerate the company’s clinical development timelines and enhance its competitive positioning.